Abstract
This strategic analysis study attempts to understand the opportunities for
contract research organisations and pharmaceutical companies to take advantage
of the inevitable choice of Phase zero or Microdosing studies in the drug
development process. The background of microdosing, industry challenges,
regulatory guidelines and competitive analysis are discussed in detail.
View Cart
